Markets:

Overview

News

Currencies

International

Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

44.80 +0.55 (+1.24%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 Next >

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields ↗

November 06, 2024

Via Benzinga

Insights Ahead: Royalty Pharma's Quarterly Earnings ↗

November 05, 2024

Via Benzinga

3 Dividend Growth Stocks to Buy Now for a Lifetime of Passive Income ↗

October 20, 2024

Buy these stocks now, and the yield on your original investment could reach a double-digit percentage long before you retire.

Via The Motley Fool

Peering Into Royalty Pharma's Recent Short Interest ↗

October 08, 2024

Via Benzinga

2 No-Brainer Dividend Stocks to Buy With $100 in October ↗

October 01, 2024

With their high yields and strong underlying businesses, these stocks are hard to pass up.

Via The Motley Fool

2 High-Yield Dividend Stocks Near 52-Week Lows: Are They Buys Now? ↗

September 28, 2024

These dividend-paying stocks offer hard-to-find high yields, but that doesn't necessarily make them good stocks to buy now.

Via The Motley Fool

NASDAQ:RPRX: good value for what you're paying. ↗

April 24, 2024

Investors should take notice ofROYALTY PHARMA PLC- CL A (NASDAQ:RPRX)—it offers a great deal for the fundamentals it presents.

Via Chartmill

Looking Into Royalty Pharma's Recent Short Interest ↗

April 04, 2024

Via Benzinga

NASDAQ:RPRX is an undervalued gem with solid fundamentals. ↗

March 29, 2024

ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX), an undervalued stock with good fundamentals.

Via Chartmill

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 18, 2024

Via Benzinga

3 High-Yield Dividend Stocks Down by More Than 39% to Buy Now and Hold at Least a Decade ↗

September 16, 2024

Now could be a great time to scoop up three stocks trading way below their previous peaks.

Via The Motley Fool

2 Unstoppable Dividend Growth Stocks You Can Buy Now With $100 ↗

September 08, 2024

These dividend payers could more than double their payouts in the decade ahead.

Via The Motley Fool

Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut ↗

September 04, 2024

Ascendis Pharma reported lower-than-expected Q2 2024 sales of $38.76 million, missing the consensus estimate of $92.7 million due to a significant adjustment to prior sales estimates. The company...

Via Benzinga

Jim Cramer: This Financial Stock Is A Buy, Core Scientific Is A 'Very Overvalued Situation' ↗

August 16, 2024

Jim Cramer discusses Snowflake, Royalty Pharma, Core Scientific and Ally Financial on "Mad Money Lightning Round."

Via Benzinga

RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q2 2024 ↗

August 08, 2024

RPRX stock results show that Royalty Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

Via InvestorPlace

Cytokinetics' Wild Ride: Can Investors Forgive The Royalty Pharma Deal? ↗

July 11, 2024

CEO Robert Blum says there are key components to the funding arrangement with Royalty Pharma that investors are missing.

Via Investor's Business Daily

Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024 ↗

June 26, 2024

Selecting strong buy biotech stocks isn’t easy when most of them don’t make money. Here are three possibilities to meet this challenge.

Via InvestorPlace

7 Biotech Stocks to Buy on the Dip: June 2024 ↗

June 24, 2024

With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.

Via InvestorPlace

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗

June 12, 2024

Via Benzinga

June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge ↗

June 05, 2024

Biotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the rest of 2024.

Via InvestorPlace

Why Is Agios Pharmaceuticals Stock Trading Higher On Tuesday? ↗

May 28, 2024

Agios Pharmaceuticals sells its 15% royalty rights on U.S. net sales of Servier's vorasidenib to Royalty Pharma for $905 million upon FDA approval.

Via Benzinga

Agios Pharmaceuticals Inks $905 Million Deal For Cancer Drug; Shares Poised To Break Out ↗

May 28, 2024

The stock is poised to break out of a cup-with-handle base after inking a deal for a cancer drug.

Via Investor's Business Daily

Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe ↗

May 23, 2024

Unlock the latest on Royalty Pharma plc & Cytokinetics Inc.'s strategic funding collaboration for aficamten's commercialization and cardiovascular pipeline expansion.

Via Benzinga

7 Dividend Stocks to Buy at a 52-Week Low ↗

May 20, 2024

For steady yields, not to mention rebound potential, consider the following seven dividend stocks at a 52-week low.

Via InvestorPlace

RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q1 2024 ↗

May 09, 2024

RPRX stock results show that Royalty Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment ↗

May 02, 2024

Amgen reported quarterly earnings of $3.96 per share which beat the analyst consensus estimate of $3.87 by 2.33%. The company said EPS decreased by 1% due to higher operating and interest expenses...

Via Benzinga

3 Pharma Stocks to Sell in April Before They Crash & Burn ↗

April 11, 2024

Discover three pharma stocks to sell in April, facing challenges and signaling potential for significant downside.

Via InvestorPlace

Billionaire Bargain Bin: 3 Stocks the Forbes 400 Loves (That You’ve Never Heard Of) ↗

April 09, 2024

These Forbes 400 stocks have wealthy founders who run them with little fanfare or attention but are worth considering for your portfolio.

Via InvestorPlace

April’s Hidden Gems: 3 Overlooked Stocks to Freshen Up Your Portfolio ↗

April 09, 2024

Discover three overlooked stocks on Wall Street with the potential for growth and diversification this April.

Via InvestorPlace

The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio ↗

March 27, 2024

With a possible rotation away from the technology space, these are the undervalued healthcare stocks to consider.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

Headline News about Royalty Pharma plc - Class A Ordinary Shares

Starting at $3.75/week.

Subscribe Today